Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RT001 Botulinum toxin type A (Dose A)
RT001 Botulinum toxin type A · 1 trial · 3 indications
The number of subjects who show improvement based on the investigator global assessment
| Arm | Type | Description |
|---|---|---|
| RT001 Botulinum toxin Type A (Dose A) | EXPERIMENTAL | RT001 (Botulinum toxin Type A) |
| RT001 Botulinum toxin type A (Dose B) | EXPERIMENTAL | RT001 (Botulinum Toxin Type A) |
| Dose C | OTHER | Vehicle Control |
| Dose D | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| RT001 Botulinum toxin type A (Dose A) | DRUG | RT001 Botulinum Toxin Type A (Dose A) |
| RT001 Botulinum Toxin Type A (Dose B) | DRUG | RT001 Botulinum Toxin Type A (Dose B) |
| Vehicle | OTHER | Vehicle Control |
| Placebo | DRUG | Placebo Comparator |
Inclusion Criteria: * Written informed consent including authorization to release health information * Female or male, 18 to 65 years of age and in good general health * Willing and able to follow study instructions and likely to complete all study requirements * Moderate to severe lateral canthal ...
RT001 Botulinum toxin type A is an investigational injectable therapy developed by Revance Therapeutics, Inc. for reducing moderate to severe lateral canthal lines, commonly called crow's feet. It is a botulinum toxin type A product studied as a nonsurgical treatment for facial wrinkles around the outer corners of the eyes.
RT001 Botulinum toxin type A is being studied for the treatment of moderate to severe lateral canthal lines, also known as crow's feet or facial wrinkles, in adults. The condition involves lines that form at the outer corners of the eyes. It is an investigational product and has not been established as an approved treatment.
RT001 Botulinum toxin type A is developed by Revance Therapeutics, Inc., which trades on the Nasdaq under the ticker RVNC. The company is the sponsor of the clinical program evaluating the product for lateral canthal lines.
RT001 Botulinum toxin type A is in Phase 2 clinical development. Its single recorded trial, a Phase 2 efficacy and safety study in adults with moderate to severe lateral canthal lines, has been completed. The program has no active trials, and the product is investigational rather than approved.
RT001 Botulinum toxin type A was evaluated in one completed Phase 2 trial, NCT01124552, titled a 4-arm efficacy and safety study of RT001 for moderate to severe lateral canthal lines in adults. The randomized, double-blind, placebo-controlled study enrolled 180 participants in the United States and is no longer active.
Yes. RT001 Botulinum toxin type A is also referred to as RT001 Botulinum toxin type A (Dose A). The parenthetical label distinguishes the dose studied in the Phase 2 lateral canthal lines program sponsored by Revance Therapeutics, Inc. Searches for either name refer to the same investigational botulinum toxin type A product.